Because BNP has natriuretic, diuretic, and vasodilatory effects, and antagonizes the activation of the renin-angiotensin-aldosterone system, it has great clinical application value.
International studies since 2000 have confirmed that BNP can further improve the symptoms and prognosis of patients with severe heart failure compared with traditional treatment (Appendix 1), and the American and European heart failure guidelines have included the drug (Appendix 2). You can find and look at domestic research, and the results are similar. At present, the reason why the drug is not widely used in China is presumed to be related to the lack of promotion by domestic manufacturers. Things in China are often like this. Everyone should understand, but think about it, it is often the case internationally, such as the current influenza A vaccine.